Finally, the integration of CDX2 with molecular biomarkers such as MSI, RAS, BRAF, or SATB2 [27] may lead to the development of comprehensive prognostic and predictive models, supporting a more personalized therapeutic approach in colorectal cancer. This evidence concerns the gene SATB2 and colorectal cancer.